Premium
Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions
Author(s) -
Drawz Sarah M.,
Marschner Susanne,
Yañez Martha,
García de Coca Alfonso,
Feys Hendrik B.,
Deeren Dries,
Coene José
Publication year - 2015
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.13026
Subject(s) - platelet , medicine , adverse effect , buffy coat , platelet transfusion , surgery
BACKGROUND Mirasol pathogen reduction technology (PRT) treatment inactivates bacteria, viruses, and parasites in plasma products and platelets (PLTs) suspended in plasma and PLT additive solutions (PAS). Few clinical studies exist documenting transfusions with PAS. This study objective was to evaluate the count increments of PRT‐treated PAS‐C and PAS‐E buffy coat (BC) PLTs in routine use observational settings. STUDY DESIGN AND METHODS PLT pools of five or six BCs were collected, processed, and suspended in PAS‐C or PAS‐E, respectively. Products were exposed to ultraviolet light in the presence of riboflavin and then transfused into 19 patients with hematologic diseases. Patients were monitored for PLT corrected count increment (CCI) at 1 and 24 hours and for any adverse events in the 72 hours after transfusion. Sterility monitoring was performed with a microbial detection system (BacT/ALERT, bioMérieux). RESULTS The PAS‐E products had significantly higher PLT concentrations and counts than the PAS‐C products. The mean CCIs of per‐protocol (PP) units at 1 and 24 hours were 11,900 (n = 27) and 5500 (n = 30), respectively. Seventy‐eight percent of PP transfusions classify as successful with CCIs at 1 hour of higher than 7500, and 63% higher than 4500 at 24 hours. One patient was excluded from all analyses as she was refractory to Mirasol‐treated PLT transfusions and follow‐up untreated transfusion products. No adverse events were observed and no contaminated products were detected by BacT/ALERT. CONCLUSION PRT‐treated BC PLTs in PAS‐C or PAS‐E demonstrate PLT transfusion success rates in hematology patients with thrombocytopenia that are comparable to previous studies examining PLTs stored in plasma.